IL‐15 Superagonist SHR‐1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment
SHR-1501 demonstrated potent antitumor activity, especially when combined with PD-1 mAb. Its mechanism likely involves promoting CD8+ T cell and NK cell infiltration and enhancing M1 macrophage activity. These findings provide evidence for further clinical trials exploring SHR-1501 in nonsmall cell lung cancer (NSCLC) therapy.
Authors
- Congli Hu (ORCID: https://orcid.org/0000-0002-3590-2739)
- Heng Luo (ORCID: https://orcid.org/0000-0003-3418-5739)
- Xuefei Li (ORCID: https://orcid.org/0000-0002-4119-4652)
- Yuanyuan Wang (ORCID: https://orcid.org/0000-0001-8471-6919)
- Minlin Jiang (ORCID: https://orcid.org/0000-0001-9812-7912)
- Qian Zhang (ORCID: https://orcid.org/0000-0002-3794-0499)
Institutions
- Tongji University (CN)
- Shanghai Pulmonary Hospital (CN)
Publication Details
- Journal
- The Clinical Respiratory Journal
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1111/crj.70117
- Citations
- 3
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China